RELIEF THERAPEUTICS HLDG AG RLFTF

hawkowl

Potential 8 month base just starting it's move off the lower support line. Classic 4 point continuation pattern. Stochastics and MACD curling up. Relief Therapeutics just held a conference call on concluding FDA Phase III trials for severe Covid using the drug Aviptadil (Zyesami). Expect filing for FDA EUA approval within a week and FDA approval in 30 days or...

AmithS

bullish fag pattern.. there are more news to come out.

michaelquale

This stock has been interesting to watch from a market perspective. There are 2.5Bn shares out there, major institutional holders, insiders buy in. But what fascinates me most, is two fold. The first is the science and open label study results. The second is the people, the team behind the science. Do your own DD, but you will find the same results. A team of...

OTCMarketsExpert

Company Details RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company. It engages in the development and licensing of its portfolio of medicinal products candidates. Its products include aviptadil, for respiratory indications such as sarcoidosis and pulmonary hypertension; and atexakin alfa, for the treatment of diabetic neuropathy. The company...

cardonajuanc

Anticipating some positive news from RLFTF's and further FDA approval for it's Aviptadil. ABCDE Triagle wave approaching completion, confirmed by Williams Alligator, and Fib Retracement A bounced off 0.382 level C bounced off 0.5 level Look for E confirmation off 0.618 level Should price exit the triangle formation, setting target @ $1.2

01:57

satish-gaire

This is a SWISS company trading in OTC but this is a REAL company with REAL DRUG. So They have an ED medication ( Aviptadil ) that hospitals might use for COVID patients with respiratory Failure They are on "FAST TRACK" For FDA Approval .20 cents is a good buy. I got in at .18 and sold and bought several times to make a profit today. but I am still in...

HotCharts

Relief Therapeutics Holding AG, a clinical stage biotechnology company, engages in developing treatment solutions for indications related to diabetic complications and respiratory diseases. The company is developing aviptadil, which has completed Phase II clinical trial for the treatment of sarcoidosis, an orphan pulmonary disease, as well as pulmonary...